Status:
RECRUITING
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combine...
Eligibility Criteria
Inclusion
- Fully understand the study and voluntarily sign the informed consent form.
- 18-75 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
- Life expectancy ≥ 12 weeks.
Exclusion
- Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Key Trial Info
Start Date :
October 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06558227
Start Date
October 24 2024
End Date
October 1 2026
Last Update
December 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China